Skip to content
Conditions & Health

Growth hormone deficiency

Inadequate production of growth hormone by the pituitary gland, causing reduced muscle mass, increased body fat, decreased bone density, and impaired quality of life. GH secretagogues and GHRH analogs are studied as alternatives to direct GH injection.

Frequently Asked Questions

What is Growth hormone deficiency?
Inadequate production of growth hormone by the pituitary gland, causing reduced muscle mass, increased body fat, decreased bone density, and impaired quality of life. GH secretagogues and GHRH analogs are studied as alternatives to direct GH injection.
Why is Growth hormone deficiency important in peptide research?
Understanding growth hormone deficiency is important because it represents a health condition where peptide interventions are being actively researched. Knowledge of the underlying pathology helps inform peptide selection and protocol design.

Related Terms

Growth hormone secretagogue

A compound that stimulates the pituitary gland to release growth hormone by activating the ghrelin receptor or GHRH receptor. Includes peptides (ipamorelin, GHRP-2, GHRP-6) and the oral compound MK-677.

GHRH

Growth hormone-releasing hormone, a 44-amino acid hypothalamic peptide that stimulates pulsatile GH secretion from the anterior pituitary. Sermorelin, CJC-1295, and tesamorelin are synthetic analogs of GHRH.

IGF-1

Insulin-like growth factor 1, a hormone produced primarily by the liver in response to growth hormone. Mediates many of GH’s anabolic effects including muscle growth, bone density, and tissue repair.

Related Peptide Profiles

Sermorelin

A synthetic GHRH analog (first 29 amino acids of GHRH) used to stimulate natural growth hormone production. Previously FDA-approved for GH deficiency diagnosis.

CJC-1295

A synthetic growth hormone-releasing hormone (GHRH) analog that stimulates pulsatile GH secretion. Available with or without DAC (Drug Affinity Complex).

Ipamorelin

A selective growth hormone secretagogue that stimulates GH release through the ghrelin receptor with minimal effect on cortisol or prolactin.

Tesamorelin

A synthetic GHRH analog FDA-approved (Egrifta) for HIV-associated lipodystrophy. Stimulates pulsatile growth hormone release.

← Back to full glossary